La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Guardion Health Sciences a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Guardion Health Sciences..

Guardion Health Sciences (OTC:GHSI) Azioni, Catena delle Opzioni

Guardion Health Sciences

Guardion Health Sciences Inc clinical nutrition company that develops and distributes clinically supported dietary supplements and medical foods. It offers a portfolio of science-based, clinically supported products designed to support consumers, healthcare professionals and providers, and their patients by supporting bone health, eye health, cardiovascular health, and brain health through nutrients such as Calcium, Vitamin D, Vitamin K, Carotenoids, and Omega-3s.

Guardion Health Sciences Inc

Milestone Scientific (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#AMEX">MLSS</a>) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 100 percent. This is unchanged from the same period last year. The company reported quarterly sales of $2.51 million which missed the analyst consensus estimate of $2.61 million by 3.75 percent. This is a 22.04 percent increase over sales of $2.06 million the same period last year.

Earnings

Earnings Misses

News

MLSS

Milestone Scientific Q3 EPS $(0.02) Misses $(0.01) Estimate, Sales $2.51M Miss $2.61M Estimate

MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) reported quarterly losses of $(1.26) per share. This is a 19.23 percent increase over losses of $(1.56) per share from the same period last year. The company reported $3.67 million in sales this quarter. This is a 733.64 percent increase over sales of $440.00 thousand the same period last year.

LIFW

MSP Recovery Q3 Adj $(1.26) Up From $(1.56) YoY, Sales $3.67M Up From $440.00K YoY

Inhibrx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBX#NASDAQ">INBX</a>) reported quarterly losses of $(2.84) per share which beat the analyst consensus estimate of $(3.81) by 25.46 percent. This is a 35.31 percent increase over losses of $(4.39) per share from the same period last year.

Earnings Beats

INBX

Inhibrx Biosciences Q3 EPS $(2.84) Beats $(3.81) Estimate

CHMI

Cherry Hill Mortgage Investment Begins Operations As Fully Integrated, Internally Managed Mortgage REIT; Plans To Continue To Pursue Management's Execution Of Residential Mortgage Investment Strategy

Everi Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVRI#NYSE">EVRI</a>) ("Everi" or the "Company"), a premier provider of land-based and digital casino gaming content and products, financial technology, player loyalty solutions, and bingo, announced today that its stockholders have voted at a special meeting of Everi stockholders (the "Special Meeting") to approve the pending simultaneous acquisition of Everi and the Gaming &amp; Digital business of International Game Technology PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) by a newly formed holding company owned by funds managed by affiliates of Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) (the "Apollo Funds") through a merger. As previously announced, pursuant to the terms of the merger agreement, Everi stockholders will receive $14.25 per share in cash for every share of Everi common stock they own immediately prior to the effective time of the merger.

EVRI

Everi Announces That Its Stockholders Have Voted To Approve The Pending Simultaneous Acquisition Of Everi And The Gaming & Digital Business Of International Game Technology By A Newly Formed Holding Company Owned By Funds Managed By Affiliates Of Apollo Global Management; Everi Stockholders Will Receive $14.25 Per Share In Cash For Every Share Of Everi Common Stock They Own Immediately Prior To The Effective Time Of The Merger

GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) reported quarterly losses of $(0.67) per share. This is a 98.98 percent increase over losses of $(65.78) per share from the same period last year.

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Q3 EPS $(0.67) Up From $(65.78) YoY

The Trade Desk Stockholders Approve Reincorporation Of Company From State Of Delaware To State Of Nevada

Atlantica Sustainable (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AY#NASDAQ">AY</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.42 by 66.67 percent. This is a 22.22 percent decrease over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $347.55 million which beat the analyst consensus estimate of $324.54 million by 7.09 percent. This is a 14.34 percent increase over sales of $303.96 million the same period last year.

Atlantica Sustainable Q3 EPS $0.14 Misses $0.42 Estimate, Sales $347.55M Beat $324.54M Estimate

XTI Aerospace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) reported quarterly losses of $(0.13) per share. This is a 80.3 percent increase over losses of $(0.66) per share from the same period last year. The company reported $918.00 thousand in sales this quarter.

XTIA

XTI Aerospace Q3 EPS $(0.13) Up From $(0.66) YoY, Sales $918.00K

From the early days of internet forums to today's thriving Reddit communities, cannabis discussions have transformed, offering unprecedented visibility into consumer preferences.  
Caleb Chen, founder of The Highest Critic and a key moderator on Reddit's largest cannabis community, has harnessed this evolution, creating a platform that fills a crucial gap: providing unfiltered, ground-level reviews at a time when the industry is dominated by dispensary marketing.
&#8220;Reviewers on <a href="https://thehighestcritic.com/">The Highest Critic </a>aren't just casual users—they're connoisseurs buying the best cannabis, whether it's from the legal market or the underground scene,&#8221; Chen shared with Benzinga Cannabis. &#8220;Their insights offer an early look at trends, often predicting which strains will become the next big thing in dispensaries.&#8221; 
This approach of gathering authentic, ground-level feedback mirrors the spirit of early online cannabis forums, where enthusiasts first connected over shared experiences.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">From Usenet To Reddit: The Evolution Of Cannabis Conversations</h3>
Chen traces the history of online cannabis discussions back to the earliest days of the internet. &#8220;Cannabis has been part of the online conversation since the ARPANET era. At the dawn of the internet, one of the first discussions was about weed,&#8221; he explained. This legacy began with Usenet, an early online network launched in the 1980s that allowed users to exchange messages in public forums. 
Usenet was a precursor to today's social media, where cannabis enthusiasts shared growing tips, strain reviews and underground market insights. The collaborative spirit of these early forums laid the groundwork for modern platforms like Reddit, where communities continue to exchange authentic, crowd-sourced information about cannabis products.
<h3 class="wp-block-heading">A Window Into Consumer Preferences</h3>
Chen pointed out how Reddit's <a href="https://www.reddit.com/r/trees/wiki/index/?rdt=49055">r/trees subreddit offers a unique opportunity for brands</a> to gauge market trends early on. &#8220;Reviewers often get their hands on tester products from breeders before they hit<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41725186/with-200-new-dispensaries-and-four-states-voting-on-legalizing-cannabis-could-marke"> dispensaries</a>,&#8221; Chen noted. &#8220;This early feedback loop can predict which cultivars will become top sellers two or three years down the line. It's a real-time look at what heavy users are seeking.&#8221;
For brands, this is invaluable. Insights shared on The Highest Critic go beyond typical <a href="https://www.benzinga.com/topic/cannabis-marketing">dispensary marketing</a>, delving into what consumers truly want. Chen explains that while dispensaries often focus on THC levels as a selling point, Reddit users are more interested in specific effects and unique terpene profiles.
&#8220;Reddit users often look beyond the THC percentage. They want to know what's good, what's worth their money, and what provides the medicinal effects they're looking for,&#8221; Chen said. &#8220;This kind of feedback can help brands refine their offerings and focus on quality, rather than just chasing the highest THC numbers.&#8221;
Read Also:<a href="https://www.benzinga.com/general/health-care/24/11/41959233/yougov-poll-reveals-what-women-want-with-weed-relax-mindfulness-and-great-deals"> YouGov Poll Reveals What Women Want With Weed: Relax, Mindfulness And Great Deals</a>
<h3 class="wp-block-heading">Moderator Challenges</h3>
&#8220;A lot of the moderation involves banning underage users and handling posts from people looking to buy weed illegally,&#8221; Chen said. &#8220;It's a collective effort. Other moderators have been quoted in articles before, responding to inquiries through the official mod mail.&#8221; 
<h3 class="wp-block-heading">How Cannabis Brands Can Leverage Reddit For Market Insights</h3>
For cannabis brands, Reddit's communities offer a unique advantage in <a href="https://www.benzinga.com/topic/cannabis-branding">understanding market trends</a>, particularly the premiumization of cannabis. Chen explained how The Highest Critic has become a trusted resource for identifying new cultivars and genetics before they reach mainstream dispensaries.
&#8220;Many of the reviews we publish are based on tester strains from breeders or small-batch growers. These are the strains that often end up being the next big thing in dispensaries,&#8221; Chen noted. &#8220;By paying attention to what reviewers are excited about, brands can get ahead of the curve and focus on strains that have a<a href="https://www.benzinga.com/markets/cannabis/24/09/40860336/marijuana-sales-hit-record-highs-in-these-6-us-states-is-marijuana-outpacing-alcohol"> strong demand</a> among connoisseurs.&#8221;
Chen also pointed out that Reddit's cannabis forums retain a grassroots, user-driven ethos. While the community provides honest feedback, brands cannot simply buy their way into the conversation.
&#8220;Brands need to engage authentically,&#8221; Chen concluded. &#8220;The community can spot a marketing ploy from a mile away. What resonates more is when a brand listens to user feedback and makes adjustments based on what people are saying on the forum.&#8221;
Read Next: <a href="https://www.benzinga.com/news/legal/24/11/41959036/trump-nominates-another-cannabis-supporter-to-cabinet-rep-matt-gaetz-for-attorney-general">Trump Nominates Another Cannabis Supporter To Cabinet: Rep. Matt Gaetz For Attorney General</a>

Cannabis

Social Media

Entrepreneurship

Retail Sales

Markets

Tech

Media

How Reddit's Cannabis Critics Are Helping Brands Spot Market Trends Before They Hit Dispensaries

Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) reported quarterly losses of $(1.43) per share. This is a 98.58 percent increase over losses of $(100.82) per share from the same period last year. The company reported $922.37 thousand in sales this quarter. This is a 27.55 percent increase over sales of $723.13 thousand the same period last year.

SCPX

Scorpius Holdings Q3 EPS $(1.43) Up From $(100.82) YoY, Sales $922.37K Up From $723.13K YoY

Fusion Fuel Green Plc ("Fusion Fuel" or the "Company") announced today that it has issued a damages claim against Hydrogenial S.A. ("Hydrogenial" or the "Investor") and its principal, Mr. Norbert Bindner, following their failure to fund the $33.5 million Subscription Agreement disclosed in the Company's Form 6-K on September 11, 2024. Under the terms of this agreement, entered into in good faith by the Company on August 28, 2024, the Investor committed to purchase an aggregate of 43,790,850 Class A ordinary shares (the "Class A Shares"), along with warrants to acquire an additional 13,137,254 Class A Shares, for a total purchase price of $33,500,000.
Pursuant to Section 3 of the Subscription Agreement, the closing was to take place on September 30, 2024, with full payment due at or before the time of the closing. Despite all conditions to closing being met, as confirmed in discussions with Hydrogenial representatives, the Investor failed to fund in a timely fashion. The Company promptly informed Hydrogenial of its breach and requested immediate resolution, and Hydrogenial subsequently provided the Company with a revised closing date of October 25, 2024; however, to date, the Company has yet to receive proceeds from the investment. This continued delay has led Fusion Fuel to pursue legal recourse.
As a direct consequence of the funding delay, Fusion Fuel has filed for insolvency for its Portuguese subsidiary, Fusion Fuel Portugal S.A., out of which the most significant portion of the Company's technology sales and project development activities had been conducted. On the advice of insolvency counsel, the Company has submitted a claim in Portugal for damages incurred due to Hydrogenial's breach. The Company notes that the Investor's obligation under the Subscription Agreement remains in effect notwithstanding the filing of the claim and the insolvency of its Portuguese subsidiary.
In response to these events, Fusion Fuel is actively exploring strategic alternatives to preserve shareholder value, including a potential transaction that management believes could complement the Company's hydrogen business and yield significant synergies. The Company expects to provide further updates in short order.

HTOO

Fusion Fuel Issues Damages Claim Against Hydrogenial S.A. For Failure To Fund $33.5M Subscription Agreement; Announces Insolvency Of Portuguese Subsidiary, Fusion Fuel Portugal S.A.; Fusion Fuel Is Actively Exploring Strategic Alternatives To Preserve Shareholder Value, Including A Potential Transaction That Management Believes Could Complement The Company's Hydrogen Business And Yield Significant Synergies

MNOV

MediciNova Receives Notice Of Allowance From US PTO For A Pending Patent Application For MN-001 (Tipelukast) To Cover 'Method To Decrease Triglyceride Synthesis In A Liver Of A Subject'

Swedish video game company Embracer Group AB's (OTC:<a class="ticker" href="https://www.benzinga.com/stock/THQQF#OTC">THQQF</a>) latest financial results show a steep drop in sales and increased net losses as the company deals with game delays, staff <a href="https://www.benzinga.com/general/gaming">reductions, and restructuring.</a>
<h3 class="wp-block-heading">Q2 Financial Summary: Declining Sales And Higher Losses</h3>
For the quarter ending Sept. 30, Embracer reported (<a href="https://www.gamesindustry.biz/embracer-pc-and-console-sales-plummet-during-q2">via</a> GamesIndustry.biz) net sales of 8.55 billion SEK (about $774 million), down 21% from the same period last year.
See Also: <a href="https://www.benzinga.com/general/gaming/24/11/41985800/gta-5-joins-novembers-playstation-plus-lineup-with-other-fan-favorites">GTA 5 Joins November&#8217;s PlayStation Plus Lineup With Other Fan-Favorites</a>
Revenue from PC and console games took the largest hit, falling by 46% year-over-year to 2.12 billion SEK ($192 million), with only a few new releases and mixed reception of existing titles such as Disney Epic Mickey: Rebrushed. 
Mobile games saw an 8% decline, with revenue down to 1.35 billion SEK. The company recorded a net loss of 390 million SEK, a slight improvement from a 562 million SEK loss in the same quarter last year.
<h3 class="wp-block-heading">Six-Month Results: Losses And Reduced Workforce</h3>
Embracer's numbers for the first half of fiscal year 2025 reveal a sharper year-over-year decline. Net sales dropped 23% to 14.4 billion SEK, and its net loss widened to 2.58 billion SEK compared to a 1.69 billion SEK profit last year. 
Workforce reductions reflect the company's major restructuring efforts, with the number of game developers dropping from 10,654 to 6,250, and total headcount falling from 15,701 to 10,450.
<h3 class="wp-block-heading">Game Delays And Studio Divestments</h3>
A significant factor in Embracer's reduced revenues was a lack of major new releases and weaker-than-expected sales of its back catalog. 
Embracer also divested Gearbox and parts of Saber Interactive, affecting its revenue from older titles. CEO Lars Wingefors said, "Parts of our PC/Console and Entertainment &amp; Services segments are still underperforming due to delays and low ROI for primarily small and mid-sized releases." Embracer also recently sold Easybrain to Miniclip in a $1.2 billion deal as part of its efforts to reduce debt and streamline operations.
The company remains focused on core projects with a view toward longer-term growth, notably with the release of Kingdom Come: Deliverance 2, set to launch on Feb. 11, 2025, which Embracer expects will bring strong interest from the gaming community.
<h3 class="wp-block-heading">Outlook: Restructuring And Future Focus</h3>
Embracer anticipates continued lower earnings through the fiscal year, with Wingefors noting that the company has created "a stronger foundation for long-term value creation" by reducing debt and capital expenditures.
Embracer is also moving forward with plans to spin off Asmodee by the fiscal year-end, further refocusing its portfolio around core segments.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/41909832/call-of-duty-black-ops-6s-pacifist-player-reaches-prestige-without-any-kills">Call Of Duty: Black Ops 6&#8217;s Pacifist Player Reaches Prestige Without Any Kills</a></li>
</ul>
Image credits: Shutterstock.

Gaming

General

THQQF

Embracer's Earnings Struggle As Game Delays, Restructuring Weigh On Results

Fortress Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBIO#NASDAQ">FBIO</a>) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(1.15) by 33.91 percent. This is a 19.15 percent increase over losses of $(0.94) per share from the same period last year. The company reported quarterly sales of $14.63 million which missed the analyst consensus estimate of $32.22 million by 54.60 percent. This is a 57.90 percent decrease over sales of $34.75 million the same period last year.

FBIO

Fortress Biotech Q3 EPS $(0.76) Beats $(1.15) Estimate, Sales $14.63M Miss $32.22M Estimate

Operating expenses slashed by 22% year-over-year, falling to $3.9 million from $4.9 million in Q3 2023, reflecting efficiency gains.

WRAP

Wrap Technologies Reports Q3 Revenue Of $593K, Bringing 9-Month Revenue To $3.6M

BM Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMTX#AMEX">BMTX</a>) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.20) by 110 percent. This is a 23.53 percent decrease over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $14.08 million which beat the analyst consensus estimate of $13.62 million by 3.36 percent. This is a 2.11 percent decrease over sales of $14.38 million the same period last year.

BMTX

BM Technologies Q3 Adj $(0.42) Misses $(0.20) Estimate, Sales $14.08M Beat $13.62M Estimate

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4303354-1&amp;h=1786564514&amp;u=http%3A%2F%2Fwww.standex.com%2F&amp;a=Standex+International+Corporation">Standex International Corporation</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXI#NYSE">SXI</a>) today announced that it has acquired Michigan-based Custom Biogenic Systems ("CBS") for approximately $6.2 million in cash. The transaction is being financed from Standex's existing cash balance. In its first year of ownership, the Company expects the acquisition to be accretive to its earnings. CBS will be reported as part of Standex's Scientific business segment.

Standex Acquires Custom Biogenic Systems For ~$6.2M In Cash

Greenland Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTEC#NASDAQ">GTEC</a>) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $0.01 by 600 percent. This is a 28.57 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $18.83 million which missed the analyst consensus estimate of $24.00 million by 21.53 percent. This is a 13.75 percent decrease over sales of $21.84 million the same period last year.

GTEC

Greenland Technologies Q3 EPS $(0.05) Misses $0.01 Estimate, Sales $18.83M Miss $24.00M Estimate

Trian Fund Management, the hedge fund led by Nelson Peltz, disclosed substantial portfolio changes in its third-quarter 13F filing, making notable exits from major companies before the <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">2024 U.S. presidential election</a>. 
What Happened: The fund sold off its entire stakes in GE HealthCare Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) (1.34 million shares), Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) (2.65 million shares) and Rentokil Initial plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTO#NYSE">RTO</a>) (470,000 shares). 
These exits suggest a cautious pivot from sectors like healthcare and entertainment, which face both market challenges and macroeconomic pressures.
Trian also reduced its stakes in several core holdings. The fund cut its position in Wendy&#8217;s Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) by 3%, reducing its shares from 31.5 million to 30.5 million, and scaled down its investment in asset manager Invesco Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) by 15%, from 27.2 million to 23.1 million shares.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a>
The most substantial reduction came in Allstate Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>), where Trian slashed its holdings by 69%, to 613,447 shares. These reductions reflect a strategic tightening in sectors affected by recent market volatility and economic uncertainty.
What Else: However, Trian strengthened its position in select companies, raising its stake in Solventum Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) from 5.36 million to 7.13 million shares, and held its positions steady in Janus Henderson Group PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>) and General Electric Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) as its top holdings.
This targeted increase aligns with Trian's confidence in sectors that may benefit from potential industrial and financial sector growth.
Soon after Trian's portfolio moves in the third quarter, Donald Trump's victory in the 2024 U.S. presidential election was confirmed, along with a Republican majority in the Senate.
Trump's policy agenda, which includes corporate tax cuts, increased tariffs and a potential rollback of green energy initiatives, is expected to significantly impact markets. 
Sectors like traditional manufacturing, defense and energy may see gains under Trump's administration, aligning with Trian's portfolio shifts, especially in industrial and financial investments.
Trian's recent moves highlight a forward-looking strategy as the hedge fund prepares for an evolving economic landscape shaped by Trump's return to the White House.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41984278/jim-simons-renaissance-technologies-shifts-gears-microsoft-in-tesla-out-palantir-on-top">Jim Simons&#8217; Renaissance Technologies Shifts Gears: Microsoft In, Tesla Out, Palantir On Top</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Hedge Funds

Politics

GEHC

Janus Henderson Group plc Ordinary Shares

SOLV

Nelson Peltz's Trian Fund Management Reshaped Portfolio Ahead Of Presidential Election

Guardion Health Sciences reports Q1 results

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Guardion Health Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/ghsi-stock-quote/">GHSI</a>) just reported results for the first quarter of 2024.<ul><li>Guardion Health Sciences reported earnings per share of -$3.71. This was below the analyst estimate for EPS of -88 cents.</li><li>The company reported revenue of $3.00 million.</li><li>This was 3.86% worse than the analyst estimate for revenue of $3.12 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ghsi-stock-earnings-guardion-health-sciences-for-q1-of-2024/">GHSI Stock Earnings: Guardion Health Sciences Misses EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GHSI Stock Earnings: Guardion Health Sciences Misses EPS, Misses Revenue for Q1 2024

Tandem Diabetes Care, Guardion Health, GT Biopharma among healthcare movers

Guardion Health Sciences (GHSI) has issued an announcement. Guardion Health Sciences, Inc. has mutually agreed with Craig Sheehan, its Chief Commer...

Guardion Health Sciences CCO Sheehan Exits with Compensation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Guardion Health Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/ghsi-stock-quote/">GHSI</a>) just reported results for the second quarter of 2024.<ul><li>Guardion Health Sciences reported earnings per share of -$1.64. This was below the analyst estimate for EPS of -66 cents.</li><li>The company reported revenue of $72,918.</li><li>This was 97.73% worse than the analyst estimate for revenue of $3.21 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ghsi-stock-earnings-guardion-health-sciences-for-q2-of-2024/">GHSI Stock Earnings: Guardion Health Sciences Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GHSI Stock Earnings: Guardion Health Sciences Misses EPS, Misses Revenue for Q2 2024

Guardion Health Sciences reports Q2 results

Guardion Health Sciences declares $5.00 dividend

Guardion Health Sciences ( ($GHSI) ) has shared an announcement. Guardion Health Sciences, Inc. has announced the departure of its President and CE...

Guardion Health Sciences CEO Jan Hall Set to Depart

Guardion Health Sciences announces adoption of plan of dissolution and liquidation

Guardion Health Sciences ( ($GHSI) ) has issued an announcement. Guardion Health Sciences, Inc. has initiated a significant corporate shakeup, anno...

Guardion Health Sciences Announces Delisting and New Interim CEO

AONC

BDRX

GHSI

GTBP

LSDI

MYMD

SABS

TNDM

XYLO

Small Cap

Opinion

Press Releases

Thinking about buying stock in Guardion Health Sciences, Minim, Revelation Biosciences, Nyxoah, or Pixelworks?

Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023

Guardion Health Sciences Announces

Guardion Health Sciences Announces its Largest Stockholder Has Voted in Favor of Proposals to Sell the Viactiv Business and the Liquidation Plan at the Company's Special Meeting of Stockholders to be held on May 23, 2024

Guardion Health Sciences Announces Approval by Stockholders of Proposed Sale of Viactiv Business

Guardion Health Sciences Announces Completion of Sale of its Viactiv® Brand and Business to Doctor's Best Inc. and Stockholder Approval of Plan of Liquidation and Dissolution

Comments

Guardion Health Sciences

Guardion Health Sciences (GHSI) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO